NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. (NBY) Revenue
Annual & quarterly revenue history · segment & region breakdown
NBY · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsNovaBay Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.01B | -100.00% |
| 2024-12-31 | $0.01B | -$0.00B | -6.45% |
| 2023-12-31 | $0.01B | -$0.00B | -27.42% |
| 2022-12-31 | $0.01B | +$0.00B | +41.16% |
| 2021-12-31 | $0.01B | +$0.00B | +2.72% |
| 2020-12-31 | $0.01B | +$0.00B | +50.54% |
| 2019-12-31 | $0.01B | -$0.01B | -47.24% |
| 2018-12-31 | $0.01B | -$0.01B | -31.39% |
| 2017-12-31 | $0.02B | +$0.01B | +53.23% |
| 2016-12-31 | $0.01B | +$0.01B | +171.56% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income NovaBay Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
NovaBay Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from NovaBay Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NBY revenue · 4 questionsNBY's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · NovaBay Pharmaceuticals, Inc. SEC filings · GAAP · NovaBay Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026